Home LiteratureArticle Details
PMID: 19909494 Published · ppublish English Journal Article Review

Epithelial to mesenchymal transition and breast cancer.

Breast cancer research : BCR ·Vol. 11 ·No. 6 ·2009-00-00 ·Pages 213

Tomaskovic-Crook E, Thompson EW, Thiery JP

Abstract

Epithelial-mesenchymal plasticity in breast carcinoma encompasses the phenotypic spectrum whereby epithelial carcinoma cells within a primary tumor acquire mesenchymal features and re-epithelialize to form a cohesive secondary mass at a metastatic site. Such plasticity has implications in progression of breast carcinoma to metastasis, and will likely influence response to therapy. The transcriptional and epigenetic regulation of molecular and cellular processes that underlie breast cancer and result in characteristic changes in cell behavior can be monitored using an increasing array of marker proteins. Amongst these markers exists the potential for emergent prognostic, predictive and therapeutic targeting.

MeSH Terms
Animals Breast Neoplasms/pathology Epithelial Cells/pathology Female Humans Mammary Neoplasms, Experimental/pathology Mesoderm/pathology
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Tomaskovic-Crook Eva
Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore 138673, Singapore. evacrook@optusnet.com.au
Thompson Erik W
Thiery Jean Paul
References (87)
87 references, click to expand
  1. Repeated observation of breast tumor subtypes in independent gene expression data sets.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 PMID: 12829800
  2. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?
    J Pathol. 2005 Aug;206(4):451-7 PMID: 15906273
  3. Molecular portraits of human breast tumours.
    Nature. 2000 Aug 17;406(6797):747-52 PMID: 10963602
  4. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis.
    Dev Cell. 2008 Jun;14(6):818-29 PMID: 18539112
  5. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells.
    Cancer Res. 2009 Apr 1;69(7):2887-95 PMID: 19276366
  6. Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
    N Engl J Med. 2004 Aug 19;351(8):781-91 PMID: 15317891
  7. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.
    Nature. 2007 Oct 11;449(7163):682-8 PMID: 17898713
  8. The epithelial-mesenchymal transition generates cells with properties of stem cells.
    Cell. 2008 May 16;133(4):704-15 PMID: 18485877
  9. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers.
    Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10069-74 PMID: 17537911
  10. Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.
    Clin Cancer Res. 2006 Nov 1;12(21):6403-9 PMID: 17085652
  11. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas.
    Oncogene. 2002 May 9;21(20):3241-6 PMID: 12082640
  12. EMT tumorigenesis in the mouse mammary gland.
    Lab Invest. 2007 Dec;87(12):1218-26 PMID: 17922020
  13. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition.
    Oncogene. 2007 Dec 13;26(57):7859-71 PMID: 17603561
  14. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.
    Breast Cancer Res. 2006;8(5):R59 PMID: 17062128
  15. Genes associated with breast cancer metastatic to bone.
    J Clin Oncol. 2006 May 20;24(15):2261-7 PMID: 16636340
  16. let-7 regulates self renewal and tumorigenicity of breast cancer cells.
    Cell. 2007 Dec 14;131(6):1109-23 PMID: 18083101
  17. Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast.
    BMC Cancer. 2009 Sep 14;9:325 PMID: 19751508
  18. Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway.
    BMC Cancer. 2007 Jan 17;7:12 PMID: 17233884
  19. Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development.
    Breast Cancer Res. 2003;5(2):101-6 PMID: 12631389
  20. Circulating tumor cells and bone marrow micrometastasis.
    Clin Cancer Res. 2008 Aug 15;14(16):5013-21 PMID: 18698019
  21. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting.
    Oncogene. 2000 Feb 21;19(8):968-88 PMID: 10713680
  22. Is there a role for circulating tumor cells in the management of breast cancer?
    Clin Cancer Res. 2008 Jun 15;14(12):3646-50 PMID: 18559576
  23. Identification of selective inhibitors of cancer stem cells by high-throughput screening.
    Cell. 2009 Aug 21;138(4):645-659 PMID: 19682730
  24. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.
    Curr Cancer Drug Targets. 2009 Mar;9(2):148-62 PMID: 19275756
  25. Histogenesis of metaplastic breast carcinoma and axillary nodal metastases.
    Pathol Int. 2009 Feb;59(2):116-20 PMID: 19154267
  26. Gene expression profiling predicts clinical outcome of breast cancer.
    Nature. 2002 Jan 31;415(6871):530-6 PMID: 11823860
  27. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.
    Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82 PMID: 1359541
  28. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.
    Cancer Res. 2008 Feb 15;68(4):989-97 PMID: 18281472
  29. Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors.
    Am J Pathol. 2002 Sep;161(3):1087-97 PMID: 12213737
  30. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.
    Clin Cancer Res. 2006 Mar 1;12(5):1533-9 PMID: 16533778
  31. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies.
    J Mammary Gland Biol Neoplasia. 2009 Mar;14(1):29-43 PMID: 19242781
  32. Collective cell migration in morphogenesis, regeneration and cancer.
    Nat Rev Mol Cell Biol. 2009 Jul;10(7):445-57 PMID: 19546857
  33. Subtypes of breast cancer show preferential site of relapse.
    Cancer Res. 2008 May 1;68(9):3108-14 PMID: 18451135
  34. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers.
    Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14867-72 PMID: 18806226
  35. Elucidating the altered transcriptional programs in breast cancer using independent component analysis.
    PLoS Comput Biol. 2007 Aug;3(8):e161 PMID: 17708679
  36. A pooled analysis of bone marrow micrometastasis in breast cancer.
    N Engl J Med. 2005 Aug 25;353(8):793-802 PMID: 16120859
  37. Ras alters epithelial-mesenchymal transition in response to TGFbeta by reducing actin fibers and cell-matrix adhesion.
    Cell Cycle. 2009 Jan 15;8(2):284-98 PMID: 19177011
  38. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.
    Cell. 2006 Jan 27;124(2):263-6 PMID: 16439202
  39. Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression.
    Am J Pathol. 1998 Mar;152(3):721-8 PMID: 9502414
  40. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients.
    Clin Cancer Res. 2007 Sep 1;13(17):5001-9 PMID: 17785550
  41. Systemic spread is an early step in breast cancer.
    Cancer Cell. 2008 Jan;13(1):58-68 PMID: 18167340
  42. Laminin 5 expression in metaplastic breast carcinomas.
    Am J Surg Pathol. 2008 Mar;32(3):345-53 PMID: 18300817
  43. The increasing complexity of the cancer stem cell paradigm.
    Science. 2009 Jun 26;324(5935):1670-3 PMID: 19556499
  44. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
    Clin Cancer Res. 2008 Jun 1;14(11):3306-11 PMID: 18519757
  45. Clinical utility of cytokeratins as tumor markers.
    Clin Biochem. 2004 Jul;37(7):529-40 PMID: 15234234
  46. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination.
    Clin Cancer Res. 2009 Apr 1;15(7):2433-41 PMID: 19318480
  47. Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas.
    Br J Cancer. 2008 Jun 17;98(12):1993-8 PMID: 18542065
  48. Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer.
    Cancer Res. 2005 Dec 1;65(23):10801-9 PMID: 16322226
  49. Epithelial-mesenchymal transitions in development and pathologies.
    Curr Opin Cell Biol. 2003 Dec;15(6):740-6 PMID: 14644200
  50. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
    Lancet. 2005 Feb 19-25;365(9460):671-9 PMID: 15721472
  51. Gene expression profiles of human breast cancer progression.
    Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 PMID: 12714683
  52. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression.
    J Pathol. 2008 Jan;214(1):25-37 PMID: 17973239
  53. Transcriptional regulation of cell polarity in EMT and cancer.
    Oncogene. 2008 Nov 24;27(55):6958-69 PMID: 19029937
  54. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells.
    Clin Cancer Res. 2005 Nov 15;11(22):8006-14 PMID: 16299229
  55. Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription.
    EMBO J. 1988 Jan;7(1):169-75 PMID: 2834201
  56. Generation of breast cancer stem cells through epithelial-mesenchymal transition.
    PLoS One. 2008 Aug 06;3(8):e2888 PMID: 18682804
  57. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer.
    Cancer Res. 2009 Jul 1;69(13):5364-73 PMID: 19549913
  58. Epithelial-mesenchymal transitions in tumour progression.
    Nat Rev Cancer. 2002 Jun;2(6):442-54 PMID: 12189386
  59. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.
    Clin Cancer Res. 2006 Oct 1;12(19):5615-21 PMID: 17020963
  60. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients.
    Breast Cancer Res. 2009;11(4):R46 PMID: 19589136
  61. Mesenchymal to epithelial transition in development and disease.
    Cells Tissues Organs. 2007;185(1-3):7-19 PMID: 17587803
  62. Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition.
    Cancer Res. 2008 Jul 1;68(13):5104-12 PMID: 18593909
  63. The epithelial-mesenchymal transition: new insights in signaling, development, and disease.
    J Cell Biol. 2006 Mar 27;172(7):973-81 PMID: 16567498
  64. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 PMID: 11553815
  65. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
    Cancer Res. 2009 May 15;69(10):4116-24 PMID: 19435916
  66. Direct evidence for epithelial-mesenchymal transitions in breast cancer.
    Cancer Res. 2008 Feb 1;68(3):937-45 PMID: 18245497
  67. Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance.
    Breast Cancer Res. 2008;10 Suppl 1:S1 PMID: 19091005
  68. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis.
    Cancer Res. 2003 Jun 15;63(12):3386-94 PMID: 12810675
  69. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells.
    Ann Oncol. 2008 Mar;19(3):496-500 PMID: 18187488
  70. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.
    Histopathology. 1991 Nov;19(5):403-10 PMID: 1757079
  71. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis.
    Cell. 2004 Jun 25;117(7):927-39 PMID: 15210113
  72. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
    Nat Cell Biol. 2008 May;10(5):593-601 PMID: 18376396
  73. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast.
    Clin Cancer Res. 2008 Apr 1;14(7):1956-65 PMID: 18381933
  74. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition.
    Nat Cell Biol. 2004 Oct;6(10):931-40 PMID: 15448698
  75. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.
    Mol Cell Biol. 1992 Mar;12(3):954-61 PMID: 1312220
  76. Generation of a functional mammary gland from a single stem cell.
    Nature. 2006 Jan 5;439(7072):84-8 PMID: 16397499
  77. Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma.
    Eur J Cancer. 2009 Jul;45(11):1979-86 PMID: 19375305
  78. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity.
    Oncogene. 2007 Oct 25;26(49):6979-88 PMID: 17486063
  79. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors.
    Cancer Res. 2004 Oct 1;64(19):7022-9 PMID: 15466195
  80. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.
    Nat Rev Cancer. 2009 Apr;9(4):265-73 PMID: 19262571
  81. Intravital imaging of cell movement in tumours.
    Nat Rev Cancer. 2003 Dec;3(12):921-30 PMID: 14737122
  82. The transcriptional repressor Snail promotes mammary tumor recurrence.
    Cancer Cell. 2005 Sep;8(3):197-209 PMID: 16169465
  83. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis.
    EMBO Rep. 2009 Apr;10(4):400-5 PMID: 19247375
  84. Epithelial-to-mesenchymal transition confers resistance to apoptosis in three murine mammary epithelial cell lines.
    Differentiation. 2006 Jun;74(5):254-64 PMID: 16759291
  85. Detection, clinical relevance and specific biological properties of disseminating tumour cells.
    Nat Rev Cancer. 2008 May;8(5):329-40 PMID: 18404148
  86. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells.
    Clin Cancer Res. 2009 Apr 15;15(8):2657-65 PMID: 19336515
  87. Glycoproteomic analysis of two mouse mammary cell lines during transforming growth factor (TGF)-beta induced epithelial to mesenchymal transition.
    Proteome Sci. 2009 Jan 08;7:2 PMID: 19128513
Article Info
Journal
Breast cancer research : BCR
Abbr.
Breast Cancer Res
ISSN
1465-542X
DOI
10.1186/bcr2416
Email
evacrook@optusnet.com.au
Published
2009-00-00
Epub
2009-00-09
Pages
213
Language
English
Region
England
NLM ID
100927353
PMCID
PMC2815537
Subset
IM
External Links
PubMed source DOI: 10.1186/bcr2416 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2